Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/106859
Title: Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP
Authors: Moriczi, Melinda
Pujol-Muncunill, Gemma
Martín-Masot, Rafael
Jiménez Treviño, Santiago
Segarra Cantón, Oscar
Ochoa Sangrador, Carlos
Peña Quintana, Luis 
González Santana, Daniel
Rodríguez Martínez, Alejandro
Rosell Camps, Antonio
Armas, Honorio
Barrio, Josefa
González de Caldas, Rafael
Rodríguez Salas, Mónica
Balmaseda Serrano, Elena
Donat Aliaga, Ester
Bodas Pinedo, Andrés
Vaquero Sosa, Esther
Vecino López, Raquel
Solar Boga, Alfonso
Moreno Álvarez, Ana
Sánchez Sánchez, César
Tolín Hernani, Mar
Gutiérrez Junquera, Carolina
Martinón Torres, Nazareth
Leis Trabazo, María Rosaura
Eizaguirre, Francisco Javier
García Peris, Mónica
Medina Benítez, Enrique
Fernández Caamaño, Beatriz
Vegas Álvarez, Ana María
Crespo Valderrábano, Laura
Alonso Vicente, Carmen
Rubio Santiago, Javier
Galera-Martínez, Rafael
García-Romero, Ruth
Ros Arnal, Ignacio
Fernández Cebrián, Santiago
Lorenzo Garrido, Helena
Viada Bris, Javier Francisco
Velasco Rodríguez-Belvis, Marta
Bartolomé Porro, Juan Manuel
Blanco Rodríguez, Miriam
Barros García, Patricia
Botija, Gonzalo
Chicano Marín, Francisco José
La Orden Izquierdo, Enrique
Crehuá-Gaudiza, Elena
Navas-López, Víctor Manuel
Martín-de-Carpi, Javier
UNESCO Clasification: 32 Ciencias médicas
320503 Gastroenterología
Keywords: Inflammatory bowel disease
Crohn’s disease
Exclusive enteral nutrition
Calprotectin
Children, et al
Issue Date: 2020
Journal: Nutrients 
Abstract: Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (μg/g) decreased significantly after EEN (830 [IQR 500–1800] to 256 [IQR 120–585] p < 0.0001). Patients with wPCDAI ≤ 57.5, FC < 500 μg/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activity
URI: http://hdl.handle.net/10553/106859
ISSN: 2072-6643
DOI: 10.3390/nu12041012
Source: Nutrients [ISSN 2072-6643], v. 12(4)
Appears in Collections:Artículos
Thumbnail
Adobe PDF (708,39 kB)
Show full item record

Page view(s)

12
checked on May 11, 2021

Download(s)

4
checked on May 11, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.